Blood test plus risk score aims to stop heart failure before it starts in diabetes patients

NCT ID NCT06593327

Recruiting now Prevention Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to screen for heart failure risk in people with type 2 diabetes. Doctors use a blood test (NT-proBNP) and a risk score to identify high-risk patients, then offer early prevention treatments. About 300 patients are taking part. The goal is to see if this screening strategy reduces heart failure and death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NT-proBNP blood test and clinical decision support tool
What this could lead to: If successful, this screening approach could help doctors identify and treat high-risk diabetes patients earlier, potentially preventing heart failure and saving lives.
What could go wrong: This is a small, early-stage study focused on screening, not a direct treatment. It may not show a clear benefit, and results may not apply to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOMETABOLIC DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Diabetic Cardiomyopathies type 2 diabetes mellitus heart failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOMETABOLIC DISEASES DIABETIC CARDIOMYOPATHY HEART FAILURE TYPE 2 DIABETES

Contacts and locations

Locations

University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.